Heat Biologics (HTBX) Tops Q2 EPS by 10c

Heat Biologics (NASDAQ: HTBX) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).

"We are pleased to report a number of important scientific, clinical and financial developments at the company,” said Jeff Wolf, Heat’s Founder and CEO. “First, the preclinical findings demonstrating that our ComPACT technology secreting the co-stimulator OX40L significantly enhanced tumor rejection were published in the journal, ‘Cancer Immunology Research.’ Additionally, we reported encouraging interim study findings from our Phase 1b trial evaluating HS-110 in combination with nivolumab (Opdivo®), a Bristol-Myers Squibb anti-PD-1 checkpoint inhibitor, for the treatment of non-small cell lung cancer.”

“We remain focused on driving shareholder value and minimizing dilution. We have implemented a number of cost-saving measures to help ensure we achieve important data readouts expected in the fourth quarter with current cash on-hand. Furthermore, I am pleased to report we have generated approximately $2.0 million in additional cash from the exercise of warrants. Significantly, we have also regained compliance with NASDAQ's minimum closing bid price requirement, which alleviates the immediacy of effecting a reverse stock split.”

“Overall, we remain encouraged by the outlook for the business and the growing interest from within the industry to utilize our platform technology with checkpoint inhibitors and other immunotherapies to activate a patient’s immune system against cancer. Importantly, our allogeneic cell-based immunotherapy has the potential to offer a broader, off-the-shelf solution that addresses many of the past challenges that have plagued the immuno-oncology market.”

For earnings history and earnings-related data on Heat Biologics (HTBX) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• F.N.B. Corp (FNB) Reports In-Line Q2 EPS
• Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue